📇 Rhumatologue · BRON CEDEX · (69) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Plateau technique de référence
Hospices Civils de Lyon (HCL) — équipements et expertise pointus pour les cas complexes
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
144.6 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
8
8 articles ont été cités au moins 8fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
425
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
178
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
7
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Aix-Marseille Université
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Definition of resectable stage III non-small cell lung cancer (NSCLC) for inclusion in clinical trials: A clinical case review by a pan-European multidisciplinary expert panel led by the EORTC Lung Cancer Group
2025ArticleLung Cancer
Les Think Tanks Syriens
2025Congrès6e CONGRÈS DES ÉTUDES SUR LE MOYEN-ORIENT ET LES MONDES MUSULMANS
Le nouveau pouvoir syrien face au champ religieux, ou les limites d’une stratégie hégémonique
2025ArticleBulletins de l'Observatoire international du religieux
Utopianism in the Middle East and North Africa
2025Ouvrage
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literature
2024ArticleCancer Treatment Reviews
Minister vs. Mufti the struggle over ‘moderate Islam’ in wartime Syria (2011–2021)
2024ArticleMediterranean Politics
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA–B GFPC 04-2020Study)
2024ArticleLung Cancer
From Jihad to Sufi ecstasy
2023Chapitre
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
HOPITAL LOUIS PRADEL - HCL
28 AV DOYEN LEPINE, 69677 BRON CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Case reports in nephrology and dialysis · 2021
Immune checkpoint inhibitors (ICIs) have revolutionized solid organ and hematologic cancer treatments by improving overall prognoses. However, they can lead to overactivation of the immune system and several immune-related adverse events and sometimes affecting the renal system. Although acute interstitial nephritis is well described, we know little about ICI-associated glomerular injury. Herein, we report an exceptional case of renal ANCA positive-associated vasculitis (AAV) after nivolumab therapy. Three weeks after the last nivolumab injection, the patient presented with proteinuria at 1.73 g/g of creatininuria, hematuria, and acute kidney injury needing dialysis associated with lung hemorrhage; anti-neutrophil cytoplasmic antibody (ANCA titer ≥1,280 with myeloperoxidase specificity of 780 U/mL) was positive, and kidney biopsy confirmed glomerular injury with crescents. The patient underwent treatment with steroid pulses, rituximab, and plasmapheresis, resulting in an improvement of the renal function and lung hemorrhage and produced a negative ANCA titer. Despite the results of the PEXIVAS study and the absence of clear benefit of plasmapheresis demonstrated in idiopathic AAV, we suggest that drug-induced AAV may be effectively treated by plasmapheresis, steroids, and rituximab.
PloS one · 2023
Introduction Considering the growing interest in matched cancer treatment, our aim was to evaluate the ability of a comprehensive genomic profiling (CGP) assay to propose at least one targeted therapy given an identified genomic alteration or signature (actionability), and to collect the treatment modifications based on the CGP test results in clinical practise for solid tumors. Methods This retrospective, multicentre French study was conducted among 25 centres that participated in a free of charge program between 2017 and 2019 for a tissue CGP test. Data were collected on the patient, disease, tumor genomic profile, treatment suggested in the report (related to the genomic profile results) and subsequent therapeutic decisions according to the physician’s declaration. Results Among the 416 patients, most had lung cancer (35.6%), followed by biliary tract cancer (11.5%) or rare cancers (11.1%); 75% had a metastatic disease. The actionability was 75.0% (95% CI [70.6%-78.9%]) for all patients, 85.1% and 78.4%, respectively in lung cancer and metastatic patients. After exclusion of clinical trial suggestions, the actionability decreased to 62.3% (95% CI [57.5%-66.8%]). Treatment modification based on the test results was observed in 17.3% of the patients and was more frequent in metastatic disease (OR = 2.73, 95% CI [1.31–5.71], p = 0.007). The main reasons for no treatment modification were poor general condition (33.2%) and stable disease or remission (30.2%). The genomic-directed treatment changes were performed mostly during the first six months after the CGP test, and interestingly a substantial part was observed from six to 24 months after the genomic profiling. Conclusion This French study provides information on the real-life actionability of a CGP test based on tissue samples, and trends to confirm its utility in clinical practice across the course of the disease, in particularly for patients with lung cancer and/or advanced disease.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Bulletin du cancer · 2026 · English Abstract
Pierret T, Descourt R, Corre R, Tomasini P, et al.
Respiratory medicine and research · 2023 · Journal Article
Veron M, Pierret T, Pérol M, Bettega F, et al.
Cancer treatment and research communications · 2022 · Journal Article
Benet J, Toffart AC, Brichon PY, Chollier T, et al.
Bulletin du cancer · 2021 · News
Courtier B, Pierret T
Lung cancer (Amsterdam, Netherlands) · 2025 · Journal Article
Brandão M, Prisciandaro E, Xenophontos E, Mariolo A, et al.
Cancer treatment reviews · 2024 · Journal Article
Désage AL, Duruisseaux M, Lafitte C, Bayle-Bleuez S, et al.
Lung cancer (Amsterdam, Netherlands) · 2025 · Journal Article
Pierret T, Greillier L, Guisier F, Daniel C, et al.
PloS one · 2023 · Journal Article
Leroy K, Audigier Valette C, Alexandre J, Boussemart L, et al.
Lung cancer (Amsterdam, Netherlands) · 2025 · Journal Article
Pierret T, Greillier L, Guisier F, Daniel C, et al.
Case reports in nephrology and dialysis · 2021 · Case Reports
Laamech R, Terrec F, Emprou C, Toffart AC, et al.
The reluctant sectarianism of foreign states in the Syrian conflict / Thomas Pierret
Arabisme et syrianité : le nationalisme du Baas au clan Assad
Dans une époque marquée par l’impact du colonialisme et les défis identitaires, le Parti Baas est un parti fondé relativement tardivement par rapport aux autres grands mouvements du nationalisme arabe.
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).